Alesta Therapeutics

About Alesta Therapeutics

Alesta Therapeutics is a Netherlands and Boston-based biotechnology company focused on developing novel oral small molecule therapies for underserved rare diseases such as hypophosphatasia (HPP) and Charcot-Marie-Tooth (CMT) disease.

Products & Services

ALE1:A unique, orally active therapeutic candidate for hypophosphatasia (HPP), a rare genetic disorder. It inhibits a novel target to reduce inorganic pyrophosphate (PPi) levels, with plans to enter clinical development in 2025.

ALE2:A promising candidate to treat Charcot-Marie-Tooth (CMT) disease by targeting chronic neurotoxicity through inhibition of GCN2, addressing tRNA mutations causing progressive muscle weakness and sensory loss.

Specialties

Small molecule therapeutics Rare disease drug development Chemistry expertise Oral administration therapies Small molecule therapies Oral therapeutics for hypophosphatasia (HPP) Therapeutics for Charcot-Marie-Tooth (CMT) disease

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series A T: - FT: Series A	A: 71500000 MR: - FA: €65 million FAN: 71500000	D: 2025-01-08 FD: 2025-01-08	7 investors

Series A Latest

2025-01-08

$71.5M

7 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

I

Ilan Ganot

Chief Executive Officer

M

Matthias Van Woensel

Chief Scientific Officer

B

Benit Maru

Chief Medical Officer

M

Madhav Gurijala

Head of Operations

L

Laura Brass

Board Member

L

Luc Dochez

Chairman of the Board

View 6 more team members with Pro

Unlock Full Team Directory

Recent News